Background: Fecal elastase-1 (E1) test is a sensitive and specific indirect test. However, there are few data on the best cut-off level in the assessment of exocrine pancreatic function in cystic fibrosis (CF). Material and methods: In 725 CF patients and 243 healthy subjects (HS) from Greece, Russia, Poland and the United Kingdom, E1 concentrations were measured. The best cut-off levels for the discrimination between CF and HS (for whole group as well as for individual countries) were calculated. Results: The best cut-off level for the differentiation between CF pancreatic insufficiency and normal pancreatic function in HS was found to be 184 mgyg of feces. However, some inter-country differences were stated. E1 concentrations in the UK subgroup were significantly lower than those found in Polish and Russian CF patients. E1 concentrations in Greek patients were significantly higher than in the other countries. However, E1 concentrations in DF508 homozygotes were very similar in all studied subgroups. In conclusion: In clinical practice, instead of a single best cut-off level for the E1 test, we suggest using a range of values (160-200 mgyg). The presence of different best cut-off levels within countries is a practical consequence of the different distribution of pancreatic function.
Introduction
The assessment of exocrine pancreatic function is one of the major diagnostic procedures in the investigation of gastrointestinal disease in cystic fibrosis (CF). Exocrine pancreatic function can be assessed by either direct Abbreviations: CF, cystic fibrosis; HS, healthy subjects; E1, fecal elastase-1; GR, Greece; PL, Poland; RU, Russia; UK, United Kingdom.
૾ Part of the data has been presented at 24th European Cystic or indirect methods, with the direct tests, such as the secretin-cholecystokinin test having the highest sensitivity and specificity w1x. However, direct tests have some major disadvantages, which make them unsuitable for routine evaluation in children, especially in those with CF. Indirect tests are more frequently used in clinical practice because they are non-invasive, simple, less time-consuming and less expensive. The development of new indirect tests has improved the diagnostic approach. From previous studies, the measurement of fecal elastase-1 (E1) concentration appears to be a good measure of pancreatic function w2-4x. The enzyme is highly specific for the pancreas and is not degraded during intestinal passage w5x. E1 No age-related differences in E1 concentrations were found. Therefore, the analysis was performed without age subgroup distribution. GR vs. PL, UK P-0.001. concentration is significantly correlated to duodenal elastase-1 output w4,6x, daily variations are low w3x and no degradation over a period of 1 week at room temperature has been reported w3,4x. In addition, the monoclonal antibodies against human pancreatic elastase do not cross-react with pancreatic preparations of animal origin making it unnecessary to discontinue enzyme replacement therapy in subjects studied w4x.
Previous studies evaluating the E1 test have generally recruited CF patients with severe exocrine pancreatic insufficiency and small groups of healthy subjects (HS) as controls w7,8x. In larger studies, the best cut-off level has not been calculated w9,10x. A value of 200 mgyg of feces is commonly used for determining exocrine pancreatic insufficiency, although there are few data concerning CF patients w4,11x. The aim of the present study is to calculate the best cut-off level for E1 in the assessment of pancreatic exocrine function in CF patients and healthy controls. The 'distribution' of pancreatic function in CF patients from different European countries has been examined to assess the variability of E1 values dependent upon genetic background.
Material and methods

Patients
Seven hundred and twenty five CF patients (357 females and 368 males) aged 2 months to 31 years wmean"S.E.M. (standard error of the mean): 10.1"0.2x were evaluated. The diagnosis of CF was based on clinical manifestations, chloride sweat concentrations ) 60 meqyl and CFTR gene analysis. Two hundred and forty three children, adolescents and adults (130 females and 113 males) aged 2 months to 52 years (mean"S.E.M.: 11.2"0.5) without gastrointestinal disease served as a control group. All subjects included in the study were from Greece (GR), Poland (PL), Russia (RU) and the United Kingdom (UK) ( Tables 1 and 2) .
The best cut-off levels for the discrimination between CF and HS were calculated. All calculations were performed for both the whole CF and HS groups as well as for individual countries (GR, PL and UK). The effect of the different 'distribution of pancreatic function' on the best cut-off level in the different countries was assessed by comparison with the whole group of HS.
The local ethics committees in each study center approved the protocol for this study.
Methods
E1 concentrations (mgyg of feces) were measured in all subjects by an enzyme-linked immunosorbent assay (ELISA; ScheBo Tech, Giessen, Germany) w12x. As ᭨ pancreatic involvement in CF has a progressive character w13x, patients under the age of 2 years were recruited to the study only if they had low E1 value (-50 mgyg).
Since normal reference values are not applicable to neonates w14x, HS younger than 1 month were excluded from the study.
Statistical analysis
The statistical differences between groups were calculated using the Kruskal-Wallis test with post test. The level of significance was set at P-0.05.
The best cut-off levels between CF patients and HS were calculated with the use of Odds ratio.
Results
The range of E1 concentrations in HS was from 167 to 1802 mgyg of feces ( Table 1 ). The overall specificity of the E1 test was 98.8% for the best cut-off level calculated in the present study (184 mgyg) and 97.5% for the best cut-off level recommended by the manufacturer (200 mgyg). The distribution of E1 results was very similar in British and Polish subgroups. However, E1 concentrations found in the HS Greek population were significantly lower (P-0.001).
The range for E1 concentrations in CF patients was from undetectable to 1810 mgyg feces ( Table 2 ). The overall sensitivity was 88.1 and 89.1% for own and 'commercial' cut-off level, respectively. The distribution of E1 results was very similar in Polish and Russian subgroups. E1 concentrations in UK subgroup were significantly lower than those found in Polish and Russian subjects (P-0.05). E1 concentrations in Greek patients were significantly higher than in the other countries (P-0.001 in all cases).
The frequency of the DF508 mutation was the highest among British and the lowest among Greek patients ( Table 3) . E1 concentrations in DF508 homozygotes were very similar in all studied subgroups. The distri-bution of E1 results in other CF patients was similar in British, Polish and Russian patients. In Greek population, however, E1 concentrations were significantly higher than in the other subgroups (P-0.001 in all cases) ( Table 4) .
With the use of E1 test, the best cut-off level for the differentiation between CF pancreatic insufficiency and normal pancreatic function in HS was 184 mgyg of feces. This level was different for each country ( Table  5 ). The highest value was found for Greek population (203 mgyg), an intermediate value for Polish (174 mgy g) and the lowest for the British subgroup (161 mgyg). For the calculation performed in relation to the whole HS group, similar inter-country differences were observed Table 5 .
Discussion
There are only two studies w4,11x, in which the best cut-off level for E1 has been previously assessed. In that of Stein et al. w4x , the optimal discrimination was found for a cut-off level of 175 mgyg. However, the study was based on non-homogenous groups of patients, comprising CF and chronic pancreatitis patients (ns54) as well as HS (ns53) and patients with non-pancreatic disorders (ns57). Walkowiak w11x in a larger CF group (ns91) defined the best cut-off level at 198 mgyg. However, the percentage (17.6%) of pancreatic sufficient patients incorporated within the study was high. For this present study, we have included a large cohort of CF patients and HS from different European countries. A value of 184 mgyg was found as a best cut-off level for the E1 test to differentiate between pancreatic insufficiency in CF and normal pancreatic function in HS. However, we have found some minor inter-country differences. Therefore, we would suggest, in clinical practice, using a range of values for E1 (for simplifi-cation 160-200 mgyg), rather than a single cut-off value, below which further investigation of pancreatic exocrine function is warranted.
The genotype predicts with a high probability the course of pancreatic disease in CF. Patients who carry two 'severe' mutations develop pancreatic insufficiency, whereas those who carry at least one 'mild' mutation usually remain pancreatic sufficient w15x. Therefore, the variable distribution of pancreatic function measured as an output of E1 in populations with different DF508 frequency stated in the present study is reasonable. The presence of different best cut-off levels is a practical consequence of this finding. Since no differences for DF508 homozygous patients were found, the higher E1 concentrations found in Greek population could be explained by the more common presence of mild mutations w15-18x.
In the present study, the percentage of CF patients (11.3%) found to have normal pancreatic function (assessed with the use of E1 test) is higher than in earlier studies assessing the applicability of the E1 test w7,8x. However, we have included complete CF populations comprising both pancreatic insufficient and sufficient patients.
In CF, the concentration of chloride, bicarbonate and water in pancreatic fluid is markedly decreased w19x. However, the amount of secreted enzymes differs significantly. Exocrine pancreatic dysfunction in CF includes disturbances of water and bicarbonate secretion but may be associated with normal enzyme output w20x. Therefore, all methods based exclusively on the measurement of pancreatic enzyme concentrationyoutput could lead to some false negative results. Moreover, as proven earlier, a small percentage of CF patients (at least temporarily) have normal pancreatic function w21x. Although E1 test is the most reliable and sensitive indirect test used in CF children w22x, its practical value in the assessment of mild pancreatic insufficiency is limited w6x.
In conclusion, 184 mgyg seems to be the best cut-off level for the E1 test in differentiating between pancreatic insufficiency in CF and normal pancreatic function in HS within the European population. In clinical practice, instead of the best cut-off level, we would suggest using a range of values (160-200 mgyg), dependent upon the country of origin. The presence of different best cut-off levels within countries is a practical consequence of the different distribution of pancreatic function (resulting from the different frequency of CFTR mutations in populations of different origin) and is likely to be true for all other tests of exocrine pancreatic function.
